Cargando…
Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
BACKGROUND: Imatinib is the first-line therapy recommended for chronic myeloid leukemia (CML) patients in China. We reported a long-term follow-up study of patients on imatinib as first-line treatment for chronic phase (CP) CML to provide an important reference for the actual clinical treatment regi...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185871/ https://www.ncbi.nlm.nih.gov/pubmed/37205184 http://dx.doi.org/10.3389/fonc.2023.1172910 |